Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff

Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.

This story was originally reported by MarketWatch. As an automated real-time news aggregator, NewsToolBar provides multi-perspective indexing and AI summarization while directing full readership directly to primary publisher sources.